Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Trial of Zhifei Human Rabies Vaccine (MRC-5 Cells)
NCT06078423Phase 3Completed
- Sponsor
- Zhifei Biological
- Start
- Oct 2019
- Primary completion
- Jul 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of human rabies vaccine (MRC-5 cells) in rabies (3 arms), sponsored by Zhifei Biological. Primary endpoints: Antibody positive conversion rate at 14 days, Geometric mean concentration at 14 days and 1 more. Started Oct 2019; status: completed.
02
Drugs
human rabies vaccine (MRC-5 cells)
03
Conditions
rabies
Beyond the preview
Go deeper on NCT06078423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06078423.